3B Blackbio DX Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹34Cr
- +17.2% YoY
- +54.5% QoQ
- Net profit
- ₹15Cr
- 0% YoY
- +15.4% QoQ
- Margin
- 43%
- −12 pp YoY
- −10 pp QoQ
Guidance rank: #34 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
3B Blackbio DX Ltd Q2 FY26 key numbers
- Revenue
- Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25.
As stated in 3B Blackbio DX Ltd's Q2 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on 3B Blackbio DX Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. H1 EBITDA (3B standalone) increased from ₹3,387.70 Lakh (H1 FY 2024-25) to ₹3,618.54 Lakh (H1 FY 2025-26).
From 3B Blackbio DX Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25.
- Exports in Q2 FY 2025-26: ₹496.71 Lakh vs. ₹366.50 Lakh in Q2 FY 2024-25.
- TRUPCR Europe Ltd (TPE) Q2 sales: GBP 404,900 vs. GBP 420,435 last year, slight decrease due to summer holidays.
- H1 FY 2025-26 revenue from operations: ₹4151.99 Lakh vs. ₹5038.89 Lakh in H1 FY 2024-25 (3B standalone MDx business).
- Consolidated H1 2025-26 revenue: ₹5613.67 Lakh vs. ₹4858.10 Lakh previous year.
- Export growth projected at 20–25%.
- TPE full-year growth expected at 20–25%.
2 more points from 3B Blackbio DX Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company acquired Coris BioConcept SRL, Belgium, for £2.15M upfront plus £0.615M earn-out, completed on August 29, 2025, marking its first acquisition to strengthen market credibility (Page 29, 42).
- Other sections focus on organic growth, marketing, contracts, and international expansion.
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- It mentions "strong order inflow" from the Middle East, indicating growing market traction (Page 21).
- Signing of long-term contracts (2-3 years) covering 20%-25% of total revenue under the Reagent-Rental Model demonstrates stability and steady business (Page 41).
- The Coris BioConcept acquisition is expected to contribute improved sales and positive EBITDA in H2, tied to its contracts including a €1.0 million government project in Belgium supplied in Nov-Dec (Page 29).
- The company has secured annual rate contracts in the Middle East, Southeast Asia, and Europe (Page 21).
3B Blackbio DX Ltd — Quarterly revenue & net profit
3B Blackbio DX Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 34 | 29 | +17.2% | 22 | +54.5% |
| Operating profit (EBITDA) | 15 | 16 | -6.2% | 12 | +25% |
| Operating margin | 43% | 55% | -12 pp | 53% | -10 pp |
| Profit before tax | 20 | 19 | +5.3% | 16 | +25% |
| Net profit (PAT) | 15 | 15 | 0% | 13 | +15.4% |
| EPS (₹) | 17.14 | 17.07 | +0.4% | 14.67 | +16.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio's management said in earlier quarters
Others in Healthcare Services this season
- Maitreya Medicare (Q2 FY26)
23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medicare's Q2 FY26 investor presentation — and how it ranks against sector peers.
- Metropolis Healt (Q2 FY26)
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
- Unihealth Hosp (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
- Indegene (Q2 FY26)
Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q2 FY26 results?
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. H1 EBITDA (3B standalone) increased from ₹3,387.70 Lakh (H1 FY 2024-25) to ₹3,618.54 Lakh (H1 FY 2025-26).
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company acquired Coris BioConcept SRL, Belgium, for £2.15M upfront plus £0.615M earn-out, completed on August 29, 2025, marking its first acquisition to strengthen market credibility (Page 29, 42).
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
